All News

Found 38 articles

• Servatus Biopharmaceuticals Joins Microbiome Therapeutics Innovation Group

  3/29/2021

  The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Australian Biotech company Servatus Biopharmaceuticals Ltd to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products.

• Microba Life Sciences appoints experienced executive Mark Capone to the Board

  3/18/2021

  Microba Life Sciences has appointed international executive, Mark Capone, as a Non-Executive Director of the Board, bringing with him more than 35 years of experience in the life sciences sector.

• Microba Life Sciences partners with Unilever to target sleep through the gut microbiome

  3/15/2021

  The Centre for Disease Control and Prevention has declared insufficient sleep a 'public health problem', with more than one-third of American adults not getting enough sleep on a regular basis.

• Microba Life Sciences Joins Microbiome Therapeutics Innovation Group

  2/22/2021

  The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Microba Life Sciences to its coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products.

• Microba co-founder and gut analysis expert to head microbiome research at QUT

  2/28/2020

  Co-founder of Brisbane-based gut analysis company Microba, Professor Gene Tyson, will head up a new field of microbiome-focused research at the Queensland University of Technology.

• Psomagen-Macrogen Consortium Acquires All Patents and Data From US Company uBiome

  1/2/2020

  On January 2nd, the Psomagen-Macrogen Consortium announced the acquisition of all key assets of US company uBiome.

• Microba founder next Southern Hemisphere VP of international society

  12/23/2019

  Co-founder of Brisbane-based gut analysis company Microba, Professor Phil Hugenholtz, has been announced as the next Vice President of the International Society for Microbial Ecology (ISME).

• Microba co-founders and Senior Bioinformatician named in 2019 Highly Cited Researchers list

  11/20/2019

  Gut microbiome analysis experts Microba had three of their researchers – including both co-founders – named in the 2019 Highly Cited Researchers list by the Web of Science Group released yesterday.

• 

  Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

  11/19/2019

  Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.

• Brisbane’s Microba represented at international competition in Berlin

  11/12/2019

  Brisbane biotech Microba were chosen to participate in international pitching competition, the Falling Walls Venture in Berlin, based on their world-leading work in analysing gut bacteria.

• Gut health testing biotech Microba wins 2019 Lord Mayor’s Innovation Award

  10/18/2019

  Brisbane-based world leaders in metagenomic testing, Microba, have won the 2019 Product Innovation Award at the Lord Mayor’s Awards Dinner tonight

• Anixa Biosciences Names Cancer Vaccine Pioneer Dr. Ian H. Frazer to Scientific Advisory Board

  10/10/2019

  Anixa Biosciences, Inc. announced the appointment of Ian H. Frazer, MD, AC, FRS, FAA, to its Scientific Advisory Board.

• Microba and Google Cloud use innovation and AI to level up gut microbiome testing

  9/27/2019

  CEO of gut health testing specialists Microba, Blake Wills, presented at the Google Cloud Summit in Sydney last week to share how working with global powerhouse Google Cloud allowed the startup to combine expert scientific knowledge with high-powered analytics and machine learning capabilities.

• Gut health testing biotech Microba up for the 2019 Lord Mayor’s Innovation Award

  9/16/2019

  Brisbane-based world leaders in metagenomic testing, Microba, are among 56 finalists competing for a Lord Mayor’s Award in October this year, as a finalist in the product innovation category.

• Brisbane-based Microba partners with UNSW Sydney’s Microbiome Research Centre to deliver world-class analysis

  8/23/2019

  Australia’s leading gut microbiome testing specialists Microba have partnered with the Microbiome Research Centre at UNSW to power new gut microbiome research to discover new links with disease states and potential therapeutics.

• Microba: Working to unlock new treatments for IBD

  7/2/2019

  Leaders in gut health testing, Brisbane-based Microba, has backed sufferers of Inflammatory Bowel Disease (IBD) through a donation of $3000 worth of sales during May to support IBD organisation Crohn’s and Colitis Australia (CCA) and the launch of a program targeted at finding relief for those with IBD in June.

• Leading Australian biotech company Microba launches IBD Therapeutic Program at BIO

  6/17/2019

  The program – launched by Queensland Minister for Innovation and Tourism Industry Development, The Honourable Kate Jones – will develop gut microbiome derived therapeutics for IBD.

• Macrogen Announces Strategic Investment in Australian Microbiome Company, Microba

  6/12/2019

  Share subscription agreement of 4.1million AUD with Microba